AI-generated research brief — verify at source
Dapagliflozin Reduces Liver Fat in Type 2 Diabetes Independent of Weight Loss
Over 12 months, dapagliflozin produced a significantly greater reduction in liver fat fraction compared to placebo (-3.7% vs. +0.5%, p = 0.001), and mediation analysis confirmed this effect was not driven by weight loss. The finding suggests the SGLT2 inhibitor may act through a direct hepatic mechanism, adding a layer of therapeutic relevance beyond its established metabolic benefits.
What Was Studied
This study examined whether the SGLT2 inhibitor dapagliflozin reduces liver fat in patients with type 2 diabetes (T2D), and crucially, whether any such reduction is mechanistically dependent on the concurrent weight loss that this drug class is known to produce. Disentangling these effects is important because metabolic-associated steatotic liver disease is highly prevalent in T2D and may warrant targeted treatment strategies.
How It Was Studied
This was a pre-specified secondary analysis of a randomized, placebo-controlled trial registered at ClinicalTrials.gov (NCT03782259). Fifty-six patients with T2D were randomly assigned to either 10 mg dapagliflozin daily or placebo and followed for 12 months. Liver fat was quantified using MRI-based proton density fat fraction (MRI-PDFF), a validated and precise imaging technique, alongside measurements of body weight, fasting glucose, HbA1c, and liver function tests at baseline and at the 12-month endpoint. The relationship between dapagliflozin use and changes in liver fat was analyzed using multiple linear regression models and formal mediation analysis, the latter designed specifically to test whether weight loss served as an intermediary pathway.
What Was Observed
- Liver fat declined substantially with dapagliflozin relative to placebo. The dapagliflozin group showed a mean reduction of 3.7 percentage points in MRI-PDFF, while the placebo group showed a slight increase of 0.5 percentage points — a difference that was statistically meaningful (p = 0.001), indicating this is very unlikely to reflect chance variation.
- Weight loss was greater with dapagliflozin but did not explain the liver fat reduction. Patients on dapagliflozin lost an average of 3.84 kg compared to 1.42 kg in the placebo group (p = 0.015); however, mediation analysis demonstrated that the indirect pathway — where weight loss would act as a mediator of liver fat change — was not statistically significant, confirming a direct drug effect on the liver.
- Glycemic control improved significantly in the treatment group. HbA1c fell by 0.52 percentage points in the dapagliflozin arm versus an increase of 0.11 in the placebo arm (p = 0.012), consistent with the known glucose-lowering profile of SGLT2 inhibitors, though this metabolic benefit also did not account for the liver fat changes in the mediation model.
- Hepatic steatosis was highly prevalent at baseline. Seventy-six percent of enrolled participants met criteria for hepatic steatosis, underscoring the clinical relevance of this cohort for studying liver-directed effects of antidiabetic therapies.
Why This Matters
The demonstration that dapagliflozin reduces liver fat through a mechanism independent of weight loss is scientifically significant because it implies the drug may engage hepatic pathways — such as altered substrate metabolism, reduced lipogenesis, or changes in hepatic energy flux — that are distinct from its systemic caloric-loss effects. This repositions SGLT2 inhibitors as potentially relevant agents in the investigation of liver-directed treatment strategies for metabolic liver disease in the T2D population. It also encourages further mechanistic research to identify the precise hepatic targets involved.
How to Read This Result
The findings come from a relatively small trial of 56 participants analyzed in a secondary framework, which limits statistical power and generalizability, and replication in larger, purpose-designed hepatic endpoint trials will be needed before strong conclusions can be drawn.
Limitations
The abstract does not explicitly report study limitations.